AZD 8871

Drug Profile

AZD 8871

Alternative Names: AZD8871

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antiasthmatics; Antibronchitics
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • Phase I Asthma

Most Recent Events

  • 19 May 2017 AstraZeneca plans a phase I trial in Healthy volunteers in United Kingdom (NCT03159442)
  • 01 Dec 2016 Phase-II clinical trials in Chronic obstructive pulmonary disease in United Kingdom, Germany (Inhalation) (NCT02971293)
  • 18 Nov 2016 AstraZeneca plans a proof-of-concept phase IIa trial for Chronic obstructive pulmonary disease in United Kingdom and Germany (Inhalation) (NCT02971293)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top